Fourteen-day continuous glucose monitoring (CGM) traces added to Diabetes Control and Complications Trial (DCCT) data can predict microvascular diabetes complications similarly to glycated hemoglobin.
The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback